A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Year to date metric has recorded a loss of -18.42%.However, over the last six months, we can see a stronger performance of -24.39%. Over the last 30 days, the price of NUVB has fallen by 9.60%. And in the last five days, it has fallen by -0.91%.
The market performance of Nuvation Bio Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $3.97 on 07/31/24, while the lowest value for the same duration was $1.54 on 04/07/25.
52-week price history of NUVB Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Nuvation Bio Inc’s current trading price is -45.34% away from its 52-week high, while its distance from the 52-week low is 40.91%. The stock’s price range during this time has been between $1.54 and $3.97. The trading volume for the Healthcare sector company’s shares reached about 5.65 million for the day, which was higher than the average daily volume of 3.07 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Nuvation Bio Inc (NUVB) has experienced a quarterly decline of -5.65% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 738.37M and boasts a workforce of 220 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.22, with a change in price of -0.50. Similarly, Nuvation Bio Inc recorded 2,792,108 in trading volume during the last 100 days, posting a change of -18.73%.
NUVB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NUVB stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.01.
NUVB Stock Stochastic Average
Today’s raw stochastic average for Nuvation Bio Inc over the last 50 days is 63.00%.This indicates a increase from the raw stochastic average of the past 20 days, which was 33.93%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 49.11% and 52.70%, respectively.
